Cost-Effectiveness Analysis of Ibrutinib-Venetoclax for Mantle Cell Lymphoma

A partitioned survival model with a 35-year simulation horizon compares the cost-effectiveness of ibrutinib-venetoclax versus ibrutinib-placebo for relapsed or refractory mantle cell lymphoma. The dataset, authored by Jing He and last updated on 2026-05-21, contains results from a cost-effectiveness analysis conducted from healthcare perspectives in China and the United States. Primary outcomes likely include total costs, life-years, quality-adjusted life-years, and incremental cost-effectiveness ratios.

Use Cases

• Evaluate cost-effectiveness of combination therapies based on incremental cost-effectiveness ratios (ICERs)
• Perform sensitivity analysis on healthcare economic models based on one-way and probabilistic sensitivity analysis results
• Compare drug pricing and willingness-to-pay thresholds across different healthcare systems based on data from China and the US

Strengths

• The model uses a 35-year simulation time horizon for long-term projections
• Analysis includes sensitivity checks via one-way sensitivity analysis (OWSA) and probabilistic sensitivity analysis (PSA)
• Provides specific ICER values for two distinct healthcare systems: $128,183.93/QALY in China and $951,082.87/QALY in the US

Limitations

• Column-level documentation is absent; field semantics must be inferred after download
• Row count is unknown, which may limit suitability assessment
• The 3.4 MB file size suggests a small dataset, potentially limiting the scope of included data

Provenance

Source

figshare

Collection Method

Partitioned survival model developed for cost-effectiveness analysis.

Time Range

35-year simulation horizon

Freshness

Last updated 2026-05-21 05:42:14

Geography

China and the United States